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In industrialized countries, viral load monitoring and genotypic antiretroviral drug resistance 
testing (GART) play an important role in the selection of initial and subsequent combination 
antiretroviral therapy (cART) regimens. In contrast, resource constraints in Africa limit 
access to assays that could detect virologic failure, transmitted drug resistance (TDR) and 
acquired drug resistance to cART. This has adverse consequences for both individual and 
public health. Although the further roll-out of antiretrovirals for prevention, including 
preexposure prophylaxis (PrEP) and universal test and treat (UTT) strategies, could reduce 
HIV-1 incidence, these strategies may increase TDR [1,2]. Here, we present arguments that 
the scale up of antiretrovirals use should be accompanied by cost-effective assays for early 
detection of virologic failure, surveillance of TDR and GART for individual patient 
management.
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It is theoretically possible to remain on the same cART regimen for life, when an individual 
is infected with an antiretroviral susceptible strain, with adequate adherence, retention, 
optimal drug bioavailability and the absence of structural barriers (e.g. cART stock outs, 
etc.) [3,4]. The desired outcome of cART is achieving and maintaining suppression of HIV 
replication with viral load below the detection limit of standard HIV-1 RNA assays (<50 
copies/ml). Adherence monitoring is required to detect lapses in adherence leading to 
virologic rebound which could benefit from adherence counseling intensification before 
emergence of drug resistance [5,6], l or switching patients to second line, who have 
sustained viral load more than 1000 copies/ml despite documented optimal adherence, 
according to WHO criteria [7]. The threshold of 1000 copies/ml is based on commercial 
GART sensitivity, but with ‘homebrew’ methods on plasma samples, drug resistance is 
often detected at lower viral load [8], whereas a higher threshold would apply for dried 
blood spots. Unfortunately, few settings in sub-Saharan Africa have access to routine viral 
load testing because of the cost, whereas clinical and immunological monitoring are only 
moderately sensitive and specific measures of virologic failure, resulting in either delayed or 
unnecessary cART switches [9–11]. New low-cost point-of-care viral load testing could 
increase access and enhance the cascade of care through immediately available results [12], 
whereas centralized testing could reduce costs by economy of scale or pooled testing 
[13,14], but would require sample transport infrastructure and ideally the use of information 
systems with confidential/coded automated mobile health text messaging of results to patient 
and providers.
When HIV replicates under conditions that favour selection of spontaneously generated, 
mutant variants, (e.g. monotherapy or dual therapy or inadequate drug concentrations), these 
drug-resistant variants would predominate. Their emergence and persistence are influenced 
by the genetic barrier to resistance (number of mutations required for resistance), 
pharmacokinetic properties including antiretroviral half-lives, relative fitness of resistant 
HIV variants compared with wild type, and interactions between mutations that may 
increase or decrease susceptibility to other antiretrovirals.
The particular regimen, chosen, impacts on the risk of resistance: thymidine analogue 
mutations (TAMs) accumulate in patients with prolonged virologic failure on stavudine 
(D4T) or zidovudine [15]; nevirapine(NVP) is associated with a higher risk of TAMs than 
efavirenz (EFV) and etravirine (ETV) [16–19]; NVP/tenofovir (TDF)/lamivudine (3TC) is 
associated with higher rates of virologic failure and K65R compared with EFV/TDF/
emtricitabine (FTC) or 3TC [20,21]; abacavir (ABC)/3TC compared with TDF/FTC 
combined with a protease inhibitor has greater rates of virologic failure and accompanied 
resistance [22,23]. Similarly, ABC/3TC/EFV has greater virologic failure compared with 
TDF/FTC/EFV in patients with high baseline viral loads [23], possibly from cross-resistance 
between 3TC and ABC resulting in a lower regimen genetic barrier.
Models dispute the cost-effectiveness of GART [24–26]. The underlying assumptions vary: 
the cost of GART (~$300 for commercial assays compared with ~$150 for homebrew tests); 
predictive value of bulk sequencing; and rates of poor adherence with first-line virologic 
failure, which impacts rates of detectable drug resistance mutations [18,25,27,28]. Although 
initial response rates to LPV/r regimens in second-line therapy is good irrespective of 
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preexisting nucleos(t)ide reverse transcriptase inhibitor (NRTI) resistance [29], GART may 
help determine the most durable NRTI backbone for a second-line regimen, or to detect 
mutations that would be relevant for future third-line or salvage regimens, which may later 
no longer be detectable by bulk sequencing. When patients fail a first-line regimen of 
TDF/3TC or FTC/non-nucleoside reverse transcriptase inhibitor (NNRTI), the resistance 
pattern is predictable, although the duration of virologic failure influences the number of 
mutations i.e. only NNRTI and/or 3TC/FTC resistance; or, even later, the addition of TDF 
resistance [30,31]. Virologic failure during second-line protease inhibitor regimens in 
resource-limited settings (RLS) is associated with less than 10% protease inhibitor resistance 
because most patients were protease inhibitor naive and lopinavir (LPV)/r provides a high 
genetic barrier to selection of antiretroviral-resistant variants [18,32,33]. Polymorphisms in 
the gag cleavage site [34] or in envelope [35,36] have been associated with protease 
inhibitor resistance. However, these mutations are not detected by routine GART and their 
contribution to protease inhibitor failure is understudied. Nevertheless, current data support 
that inadequate drug exposure from poor adherence is the major contributor to virologic 
failure [37,38].
When the pretest probability of resistance is low, such as with virologic failure during 
second-line cART, blanket resistance testing would not be cost-effective. ART adherence 
assessed by objective tools such as pharmacy refill data [39] or hair concentrations [40] 
predictive of poor adherence [37] could identify individuals requiring adherence 
interventions [41]. Reserving GART for patients for whom virologic failure is unexplained 
by very poor adherence would optimize resource allocation [37]. In a context of documented 
virologic failure, therapy and adherence history and by GART testing, when available and 
affordable, will be critical to identify patients requiring third line and to construct regimens, 
which include darunavir and raltegravir.
TDR from primary or ‘super-infection’ is associated with increased cART coverage [42] and 
inadequate management of persons with virologic failure [43]. The WHO suggests 
surveillance of TDR in young persons, more likely to have recent infection and less likely to 
have TDR mutations overgrown by wild-type virus [44,45], and defines a prevalence of less 
than 5% as ‘low’, 5–15% as ‘intermediate’ and more than 15% as ‘high’ [46]. However, the 
largest studies of antiretroviral-naive patients assessed GART at cART initiation [42,47,48]. 
Currently, the WHO is considering adding this practical surveillance strategy. Recent data 
suggest increased TDR in RLS [48–52]. In contrast, data from South Africa suggest that 
TDR may have peaked [53], perhaps due to viral load monitoring [43].
New biologic approaches to HIV prevention, including PrEP and UTT strategies, are 
gaining momentum. In studies of PrEP, the major risk for resistance appears to be initiation 
of mono- or dual-drug PrEP during undiagnosed primary HIV infection [54–57]. As UTT 
and PrEP often rely on TDF as a regimen component, the possible more rapid selection of 
K65R in HIV-1 subtype C [58–61], although abrogated by other mutation interactions[62], 
is of concern for regions of sub-Saharan Africa where this subtype predominates. In clinical 
trials of PrEP, HIV testing to detect incident HIV infection occurred monthly, but with 
expansion to RLS this is likely to occur less frequently, increasing the risk for selection of 
drug-resistant variants which may emerge if failure of PrEP occurs unnoticed (e.g. due to 
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suboptimal adherence), and as a consequence, the HIV infection being exposed to 
suboptimal dual therapy (FTC/TDF) instead of full cART [63,64]. Therefore, monitoring of 
PrEP adherence as well as implementation of targeted adherence interventions, when 
necessary, will be critical for the optimization of clinical and public health benefit of PrEP 
[41]. Although models suggest variable effects of PrEP on resistance [65–67], the effects of 
cART failure on resistance prevalence are much greater [66–68].
Drug resistance testing at the time of HIV-1 diagnosis may not be efficient as TDR levels 
are less than 10%. Children infected, despite current highly effective PMTCT regimens, may 
have an increased risk of resistance and need prioritization [69,70]. Increased access to 
GART would be facilitated by new technologies (Table 1). Given that relatively few 
antiretroviral agents are available in Africa, testing for resistance with point mutation assays 
[71,72] may be worthwhile before first-line or second-line cART regimens or after single-
dose NVP exposure [73]. In-house GART methods and collective bargaining with suppliers 
– as the case of the Southern African Treatment and Resistance Network –can make testing 
more affordable, when performed by laboratories participating in international external 
quality-assurance programmes. Sequencing reverse transcriptase amino acid positions 41–
230 is sufficient for patients with virologic failure during first-line ART, and could reduce 
costs [74], as could approaches that combine screening for virologic failure with sequencing 
for reverse transcriptase mutations using pooled specimens [75,76] or next generation 
sequencing (NGS) [77]. Deep sequencing with NGS platforms to detect minor variant 
NNRTI probably adds clinical value [78] but is costly. An alternative use of NGS coverage 
is the pooling of many individually ‘primer barcoded’ samples, potentially making this an 
affordable alternative to GART by bulk sequencing in a centralized high-throughput 
laboratory service [79].
In summary, the recent and dramatic increase in cART coverage in Africa is associated with 
an increase in HIV drug resistance. The possible widespread use of UTT and/or introduction 
of PrEP may escalate TDR and acquired resistance, emphasizing the need for TDR 
surveillance and new affordable technologies to manage cART. Optimally, low-cost assays 
are needed that can be performed while patients wait in the clinic. An ideal assay would 
detect both virologic failure and important resistance mutations on a single platform at the 
point of care.
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Table 1
The major strengths and challenges of current technologies for genotypic antiretroviral resistance testing.
Method Strengths Challenges
Dye terminator ‘consensus’ or 
‘population’ sequencing
Mutations correlated with reference to clinical outcomes Limited potential for automation
Cost savings can be incurred by the use of in-house 
methods, shorter fragment sequencing and the use of 
qualitative polymerase chain reaction (PCR) for 
screening of patients with possible failure without 
performing viral load testing [75]
Not suited for parallela testing
Cannot detect variants that occur at a low 
frequency
Point mutation assays (e.g. 
allele-specific PCR, 
oligonucleotide ligation assays 
and multiplex allele-specific 
assays)
High sensitivity for minor variants No commercial assays available
Relatively economical Multiplexing allows for detection of a set of 
common mutations only
Next generation sequencing 
(various platforms including: 
454, Illumina and Ion torrent 
sequencers)
Parallel testing: ability to pool multiple labelled 
specimens is cost-saving
Complex workflow is labour intensive
High sensitivity for minor variants (ultradeep sequencing) Requirement for specialised facilities
Long turn-around times
PCR errors can lead to overestimating 
resistance
Possible read problems dependent on template 
compositionb
a
Parallel testing refers to the ability to test multiple HIV templates in a viral population. In addition, many patients can be tested at once through 
the use of ‘barcoding’ or ‘indexing’ the sequences. Although a single next generation sequencing reaction is costly this may allow for pooled 
testing of multiple samples. Allele-specific assays are more affordable than dye terminator sequencing or next generation sequencing, and can 
suffice if the requirement is to look for a few specific mutations; however, when required to detect more mutations, this approach become more 
costly.
bAssays that are dependent on pyrosequencing (e.g. 454 and Iontorrent) may be inaccurate in determining the sequence in regions with 
homopolymers, whereas sequencing by synthesis methods (e.g. Illumina) may be prone to unequal sequencing coverage depending to the CG : AT 
composition of the genome.
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